Blog - Page 3 of 5383 - QualityStocks

TuesdayJul 01, 2025 9:20 am

QualityStocksNewsBreaks – Golden Triangle Ventures Inc. (OTC: GTVH) Restructures $7 Million in Legacy Debt, Secures Repurchase Option

Golden Triangle Ventures (OTC: GTVH) (“GTV”) has completed a major restructuring of its capital structure and legacy debt obligations through an agreement with a new third-party investor, who acquired all outstanding notes previously held by the Company’s largest creditor, T&K Zarro, LLC. The transaction consolidates five debt instruments totaling over $7 million and grants GTVH the exclusive right to repurchase the full balance for $4 million, offering a significant discount. The move simplifies GTVH’s balance sheet, supports disciplined growth and strengthens financial positioning. To view the full press release, visit https://ibn.fm/ynhAO About Golden Triangle Ventures Inc. Golden Triangle Ventures is a…

TuesdayJul 01, 2025 9:10 am

QualityStocksNewsBreaks – Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM) Amends Payment Schedule for Iska Iska Interest, Updates Adjacent Property Agreement

Eloro Resources (TSX: ELO) (OTCQX: ELRRF) (FSE: P2QM) has reached a mutual agreement with Empresa Minera Villegas S.R.L. to amend the payment terms for acquiring 100% interest in the Iska Iska silver-tin polymetallic project in southern Bolivia. Of the remaining US$4.45 million owed, US$1.8 million in exploration spending on the adjacent Mina Casiterita property will be credited, with cash payments of US$1 million due July 15, 2025, and US$1.65 million due January 6, 2026. The related Mina Casiterita and Mina Hoyada option agreement has also been revised, calling for a US$1.8 million payment within 12 months of securing mining rights…

TuesdayJul 01, 2025 9:00 am

Dynamic Global Events Presents: The 6th Clinical Trial Agreements Summit

Dynamic Global Events (“DGE”) is proud to announce the 6th Clinical Trial Agreements Summit taking place August 21-22 in Philadelphia. This event will explore how to negotiate budgetary restraints, protect intellectual property and clinical data, and reduce risks in indemnification and subject injury. This summit offers a dynamic mix of panel discussions, fireside chats, solo presentations, and exclusive networking opportunities with top stakeholders across the clinical research industry. Hear from 30+ expert speakers representing leading organizations including Merck, Pfizer, Takeda, Alkermes, and many more. As clinical trial agreements form the foundation of every collaboration between sponsors, sites, and CROs, it’s essential…

TuesdayJul 01, 2025 9:00 am

QualityStocksNewsBreaks – Channelchek by Noble Highlights Aurania Resources (TSXV: ARU) as 2D Inversion Reveals Six Conductive Anomalies at Awacha

Channelchek, a Noble Financial Group, Inc. product and service, reports that Aurania Resources (TSXV: ARU) identified six highly conductive anomalies at its Awacha porphyry copper target in Ecuador using updated two-dimensional inversion technology on 2021 MobileMT survey data. The advanced 2.5D algorithm, which factors in local topography, provided enhanced subsurface mapping and confirmed deep-rooted conductivity zones beginning 250 meters below surface. These anomalies are considered promising for porphyry copper exploration due to their correlation with conductive sulphide mineralization and porphyry-related alteration. To access the full report, visit https://ibn.fm/uO04N About Noble Capital Markets Established in 1984, Noble Capital Markets is an…

MondayJun 30, 2025 3:45 pm

QualityStocksNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Advancing Novel Immunotherapy to Combat Antibiotic Resistance

Soligenix (NASDAQ: SNGX) is at the forefront of the effort as the medical community urgently seeks alternative treatments for bacterial infections in the face of escalating antibiotic resistance. The company’s SGX943 therapy “is based on dusquetide, an Innate Defense Regulator (‘IDR’) that modulates the body’s immune response rather than directly targeting bacteria. By enhancing the innate immune system, SGX943 promotes the clearance of infections and reduces inflammation, offering a broad-spectrum approach to bacterial infections,” reads a recent article. “The company’s portfolio encompasses both specialized biotherapeutics and public health solutions, targeting areas with significant unmet medical needs.” To view the full article,…

MondayJun 30, 2025 2:42 pm

QualityStocksNewsBreaks – Vivakor Inc. (NASDAQ: VIVK) Poised for Opportunity at the Nexus of Energy and Innovation

As governments, consumers, and investors demand cleaner practices and corporate accountability, companies are being urged to innovate and adapt—or risk falling behind. Vivakor (NASDAQ: VIVK), a vertically integrated energy infrastructure and environmental services company, is positioned for this challenge. Engaged in the transportation, storage, reuse, and remediation of oilfield fluids and waste, Vivakor is proving that environmental responsibility and profitability are not mutually exclusive. Looking ahead, “Vivakor is focused on expanding its environmental services segment, investing in infrastructure that enhances waste oil processing, and advancing technologies that reduce emissions and environmental impact. By positioning itself at the intersection of energy production…

MondayJun 30, 2025 1:12 pm

QualityStocksNewsBreaks – Why Lantern Pharma Inc. (NASDAQ: LTRN) Is ‘One to Watch’

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company, is leveraging artificial intelligence and machine learning to redefine oncology drug development. Through its proprietary platform, RADR(R) (Response Algorithm for Drug Positioning & Rescue), Lantern is advancing a pipeline of precision cancer therapies. “Lantern Pharma’s AI-driven RADR(R) platform integrates over 200 billion oncology-specific data points and underpins every stage of its precision oncology pipeline,” reads a recent article. “The company has three lead drug candidates in clinical development, targeting major oncology markets including non-small cell lung cancer (‘NSCLC’), triple-negative breast cancer (‘TNBC’), and non-Hodgkin’s lymphoma (‘NHL’)… Starlight Therapeutics extends Lantern’s footprint into…

MondayJun 30, 2025 10:30 am

Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) Set to Capitalize on Potential of Nevada’s Walker Lane

Nevada’s Walker Lane area is becoming a prime target for mineral exploration Lahontan Gold is focused on becoming a strategic player in the Walker Lane region Lahontan’s strategic execution, focused on resource growth and economic evaluation, mirrors the broader resurgence of Walker Lane as a target-rich environment LGCXF recently launched new metallurgical testing at its Santa Fe deposit, aiming at improving gold and silver mineralization Nevada’s Walker Lane region has emerged as one of North America’s most compelling gold and silver frontiers — and Lahontan Gold (TSX.V: LG) (OTCQB: LGCXF) is strategically placed to capitalize on that fact, owning and developing four…

MondayJun 30, 2025 9:45 am

Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Secures Multimillion-Dollar Funding from U.S. Department of Defense to Strengthen Rare Earth Independence

Despite the critical importance of rare earth element metals, the United States has long been dependent on imports to provide an adequate supply. Ucore has secured a $18.4 million funding agreement from the U.S. DoD to support the development of its rare earth processing facility in Louisiana. Ucore CEO notes that the funding validates the company’s technological leadership, underscores the strategic value of domestic REE processing. As global competition intensifies over the control and supply of critical minerals, the United States is taking aggressive steps to secure domestic sources of rare earth elements (“REEs”)—materials essential for defense systems, electronics and clean energy.…

MondayJun 30, 2025 9:30 am

QualityStocksNewsBreaks – Clene Inc. (NASDAQ: CLNN) Advances Regulatory Strategy for CNM-Au8 with FDA Meetings Scheduled for ALS and MS Programs

Clene (NASDAQ: CLNN) announced key regulatory developments following a Type C meeting with the FDA, where it received feedback on its statistical analysis plan (SAP) for evaluating neurofilament light (NfL) biomarker data from its Expanded Access Protocol for ALS. The company has resubmitted a revised SAP and anticipates FDA acceptance this summer, with NfL analyses scheduled for early Q4 2025 to support a potential NDA submission under the accelerated approval pathway. Clene also confirmed two additional FDA meetings in Q3 2025: one to assess long-term ALS survival data for accelerated approval consideration and another End-of-Phase 2 Type B meeting to review…

Site Search

Company Search